VEGFA and glioblastoma: Based on the knowledge that GBM is highly vascular and expresses high levels of the angiogenic mediator vascular endothelial growth factor (VEGF), there have been several clinical works on systemically administering anti‐VEGF monoclonal antibodies.[33] However, the result is not as expected due to the natural obstacles of the BTB.